Don't Pfizer's Honchos Read Ming's Blog?

Ming assumes Jeff Kindler would be ashamed not to wear a mask if he stole Dendreon at say, $12 a share. As the new CEO of Pfizer, Jeff was smart enough to create an oncology division to develop, license and purchase biotherapeutics and new bioinnovations. He put heavy hitter Marty Mackey in as President and the equally well qualified Briggsy Morrison in as head of clinical development with the redoubtable Cory Goodman heading up research. Tell poor Ming that with all that talent and brains, they're not in the market to hit a home run with the purchase of a baby biotech with three phase III trials in a lucrative indication such as prostate cancer. Slip $2.50 in tax benefits in Pfizer's pocket as they walk in the door. Get a pipeline that can be developed to dominate the oncological landscape for at least a generation. Why does poor Ming living under a bridge have to do all the thinking for this well recompensed braintrust?